Search Results

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.

Aurorium, a specialty ingredients manufacturer and materials innovation partner, is pleased to announce the launch of Haelium™ Pharmaceutical Solutions.

Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.

NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an important drug for cancer patients to Latin America.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will expand its ongoing Netherton Syndrome clinical studies to include international sites.